Table 2.
Treatment administration.
| TLC treatment | Number of patients (%) (N = 285) |
|---|---|
| STARTING REGIMENS | |
| TL+ capecitabine | 116 (40.7) |
| TL+ vinorelbine | 61 (21.4) |
| TL+ paclitaxel | 33 (11.6) |
| TL+ paclitaxel+ carboplatin | 17 (6.0) |
| TL+ gemcitabine | 14 (5.0) |
| TL+ docetaxel | 13 (4.6) |
| TL+ vinorelbine + capecitabine | 7 (2.5) |
| Other | 24 (8.4) |
| Maintenance treatment regimen | 93 (33.0) |
| TL | 22 (23.7) |
| TL+ capecitabine | 20 (21.5) |
| T+ CT | 18 (19.4) |
| L+ CT | 18 (19.4) |
| TL+ endocrine therapy | 7 (7.5) |
| TL+ another CT | 5 (5.4) |
| T | 3 (3.2) |
| LAPATINIB | |
| Starting dosage (mg/day) | |
| 1,250 | 141 (49.5) |
| 1,000 | 99 (34.7) |
| 750 | 37 (13.0) |
| 500 | 8 (2.8) |
| Dose reduction (mg/day) | |
| 1,250 → 1,000 | 27 (9.5) |
| 1,250 → 1,000 → 750 | 4 (1.4) |
| 1,000 → 750 | 17 (6.0) |
| 1,000 → 750 → 500 | 4 (3.5) |
| 1,000 → 750 → 1000 | 1 (0.4) |
| 750 → 500 | 3 (1.1) |
| Dose escalation (mg/day) | |
| 500 → 750 → 1,000 | 1 (0.4) |
| 1,000 → 1,200 | 5 (1.8) |
| Interruption of lapatinib treatment | 30 (10.5) |
| Lapatinib treatment discontinuation due to AEs | 16 (5.7) |
| CHEMOTHERAPY | |
| Dose reduction | |
| Yes | 53 (18.6) |
| No | 232 (81.4) |
T, trastuzumab; L, lapatinib; C; chemotherapy; AEs, adverse events.